Skip to main content

Table 1 Sensitization of cervical cell lines SiHa and CaSki to ABT-263 by A-1210477 and vice versa

From: Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines

  SiHa CaSki
A-1210477, μM ABT-263 IC50 (μM), fold sensitization by A-1210477
0 10.11 ± 0.34   3.4 ± 0.13  
4 2 ± 0.15 5.1*** 0.3 ± 0.0013 11.3***
ABT-263, μM A-1210477 IC50 (μM), fold sensitization by ABT-263
0 19.85 ± 0.53   7.6 ± 0.11  
2    0.9 ± 0.13 8.4****
4 2.58 ± 0.2 7.7***   
  1. The IC50 values are doses of drug 1 (bolditalics) that kill 50% of the cells surviving the shown doses of drug 2 (italics). Fold sensitization IC50 drug 1/IC50 drug 2. Errors are SEM, n = 4
  2. Statistically significant differences with the IC50 of drug 1 (bolditalics) are shown as *** p ≤ 0.001 or **** p ≤ 0.0001 determined by two-tailed paired T test. Where the IC50 was not calculable, the lower bound was employed